Industry Source (OTC:INSO) Stock, Quote.Headers.trade-ideas

Industry Source Consulting Inc is a developmental company focused on CBD product manufacturing. The company currently operates as a supplement company with brands such as N8Essentials. The Company operates with core competencies in formulation and lab testing, and by contract, manages a full-scale manufacturing certified organic 275-acre indoor and outdoor farm.

INDUSTRY SRCE CONSULTING by Industry Source Consulting, Inc.

Industry Source Consulting Inc

INSOURCE CO LTD by INSOURCE CO LTD.

News

Management

TCBI

Texas Capital Bancshares Names Rob C. Holmes, Its President & CEO And Existing Board Director, To Also Serve As Chairman

Financial Highlights for Fiscal 2025 Third Quarter
(Year over Year (YoY) growth % is based on constant currency(1))
•
Gross Bookings(3)increased by 26.8% YoY in 3Q25 to $2,612.4 million.
•
Adjusted Margin(2) – Air Ticketing increased by 20.0% YoY in 3Q25 to $93.8 million.
•
Adjusted Margin(2) – Hotels and Packages increased by 24.9%YoY in 3Q25 to $121.9 million.
•
Adjusted Margin(2) – Bus Ticketing increased by 31.3%YoY in 3Q25 to $35.0 million.
•
Adjusted Margin(2) – Others increased by 53.9%YoY in 3Q25 to $19.8 million.
•
Adjusted Operating Profit(2) improved to $46.0 million in 3Q25 versus $33.4 million in 3Q24, reflecting an improvement of $12.6 million YoY.
•
Adjusted Net Profit(2) improved to $44.9 million in 3Q25 versus $38.9 million in 3Q24, reflecting an improvement of $6.0 million YoY.

Earnings

MMYT

MakeMyTrip's 3Q FY25 Gross Bookings Rose 26.8% YoY To $2.61B

WNS Sees FY25 Revenues Between $1.255B-$1.271B (Prior View:  $1.250B-$1.296B), Adjusted EPS Between $4.46-$4.55 Vs. $4.22 Estimate (Prior View: $4.13-$4.35)

Barclays analyst Emily Field downgrades Galapagos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLPG#NASDAQ">GLPG</a>) from Equal-Weight to Underweight.

Downgrades

Analyst Ratings

GLPG

Barclays Downgrades Galapagos to Underweight

Nano Labs Reports Launch Of Its Next-generation V2 Series Home Mining Equipment

Both Harvard University and Johns Hopkins University sites were recently added as participating sites in FLAMINGO-01 in the US and both principal investigators, Laura Spring and Cesar Santa-Maria have joined the Steering Committee.

GLSI

Greenwich LifeSciences Reports Initiation Of New Clinical Sites In US

Goldman Sachs analyst Gabriela Borges downgrades Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) from Buy to Sell and lowers the price target from $261 to $200.

Price Target

VEEV

Goldman Sachs Downgrades Veeva Systems to Sell, Lowers Price Target to $200

Earnings Beats

MakeMyTrip Q3 2025 Adj. EPS $0.39 Beats $0.32 Estimate, Sales $267.362M Beat $265.176M Estimate

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6" rowspan="1">Membership Guidance Summary</td>
</tr>
<tr>
<td colspan="6" rowspan="1">(Unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2024 Actual</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Year-End Medical Enrollment (in 000s)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Commercial Fee-Based</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27,199</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27,300 - 27,600</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Commercial Risk-Based</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">5,150 - 5,350</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medicaid</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8,917</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">8,600 - 8,900</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medicare Advantage</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,066</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">2,200 - 2,250</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Medicare Supplement</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">891</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Approximately 850</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Federal Employee Program</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">1,661</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Approximately 1,650</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Fee-Based</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27,199</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">27,300 - 27,600</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Risk-Based</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">18,535</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">18,450 - 19,000</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">45,734</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">45,750 - 46,600</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Large Cap

Guidance

Health Care

General

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

Elevance Health Expects 2025 Year-End Medical Enrollment Of 45.75M-46.6M

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="6" rowspan="1">Financial Guidance Summary</td>
</tr>
<tr>
<td colspan="6" rowspan="1">(Unaudited)</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2024 Actual</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full Year 2025 Outlook</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Premium Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$144.2 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low double digit growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Product Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$22.6 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Low single digit growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Service Fees</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$8.4 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Approximately flat</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Operating Revenue</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$175.2 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">High single to low double digit growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Benefit Expense Ratio</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">88.5%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">89.1% +/- 50 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Expense Ratio</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">10.6%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">10.4% +/- 50 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Operating Gain</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.3 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$9.55 - $9.85 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Other Pre-Tax Items:</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Investment income</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$2,051 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$1,875 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($1,185) million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($1,475) million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Amortization of Intangible Assets</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($580) million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($580) million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Net Pre-Tax Income (Expense)</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$286 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">($180) million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Effective Tax Rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">24.6%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">22.0% - 24.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$25.68</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$30.40 - $31.10</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted Diluted EPS</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$33.04</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$34.15 - $34.85</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Diluted Shares</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">232.9 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">225 - 226 million</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Cash Flow</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$5.8 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Approximately $8.0 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Segment Level Guidance Metrics</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Operating Revenue Growth Rate</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Health Benefits</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$150.3 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">High single digit growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CarelonRx</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$36.0 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Mid teens growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Carelon Services</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">$18.0 billion</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Greater than 50% growth</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">GAAP Operating Margin vs. 2024</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Health Benefits</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">4.2%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(50) - (25) bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">CarelonRx</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">6.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">0 - 20 bps</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Carelon Services</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">4.0%</td>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">(100) - (50) bps</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

Elevance Health Expects 2025 Adjusted EPS Of $34.15-$34.85 Versus Consensus Of $34.58, With High Single To Low Double Digit Growth In Total Operating Revenue

WNS (Hldgs) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WNS#NYSE">WNS</a>) reported quarterly earnings of $1.04 per share which met the analyst consensus estimate. This is a 11.86 percent decrease over earnings of $1.18 per share from the same period last year. The company reported quarterly sales of $319.100 million which beat the analyst consensus estimate of $316.164 million by 0.93 percent. This is a 1.01 percent increase over sales of $315.900 million the same period last year.

WNS (Hldgs) Q3 2025 Adj. EPS $1.04, Inline, Sales $319.100M Beat $316.164M Estimate

Goldman Sachs analyst Neil Mehta maintains Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) with a Buy and raises the price target from $51 to $52.

Goldman Sachs Maintains Buy on Baker Hughes, Raises Price Target to $52

Texas Capital Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>) reported quarterly earnings of $1.43 per share which beat the analyst consensus estimate of $1.08 by 32.41 percent. This is a 120 percent increase over earnings of $0.65 per share from the same period last year. The company reported quarterly sales of $283.681 million which beat the analyst consensus estimate of $283.224 million by 0.16 percent. This is a 15.39 percent increase over sales of $245.850 million the same period last year.

Texas Capital Bancshares Q4 2024 Adj. EPS $1.43 Beats $1.08 Estimate, Sales $283.681M Beat $283.224M Estimate

The U.S. Patent Office granted Patent No. US 12,191,469 B2 for Beam Global's PCC spacer product, which introduces an innovative manufacturing process that prevents thermal runaway propagation in Li-ion battery packs.&nbsp;

BEEM

Beam Global Secures New Patent For High-Volume Battery Assembly And Safety Technology

Dividends

Elevance Health Declared First Quarter 2025 Dividend Of $1.71, Up 5%, Payable On March 25, 2025, To Shareholders Of Record At The Close Of Business On March 10, 2025.

Banc of California (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BANC#NYSE">BANC</a>) reported quarterly earnings of $0.28 per share which beat the analyst consensus estimate of $0.23 by 21.74 percent. The company reported quarterly sales of $235.28 million which missed the analyst consensus estimate of $246.81 million by 4.67 percent. This is a 55.77 percent increase over sales of $151.05 million the same period last year.

Earnings Misses

BANC

Banc of California Q4 2024 GAAP EPS $0.28 Beats $0.23 Estimate, Sales $235.28M Miss $246.81M Estimate

Elevance Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELV#NYSE">ELV</a>) reported quarterly earnings of $3.84 per share which beat the analyst consensus estimate of $3.81 by 0.79 percent. This is a 31.67 percent decrease over earnings of $5.62 per share from the same period last year. The company reported quarterly sales of $44.99 billion which beat the analyst consensus estimate of $44.86 billion by 0.28 percent. This is a 5.97 percent increase over sales of $42.45 billion the same period last year.

Elevance Health Q4 2024 Adj EPS $3.84 Beats $3.81 Estimate, Sales $44.99B Beat $44.86B Estimate

Pacific Premier Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBI#NASDAQ">PPBI</a>) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.31 by 12.9 percent. This is a 31.37 percent decrease over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $144.51 million which beat the analyst consensus estimate of $142.92 million by 1.11 percent. This is a 13.29 percent decrease over sales of $166.66 million the same period last year.

PPBI

Pacific Premier Bancorp Q4 EPS $0.35 Beats $0.31 Estimate, Sales $144.51M Beat $142.92M Estimate

BMO Capital analyst Brian Pitz downgrades Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) from Outperform to Market Perform and lowers the price target from $160 to $145.

BMO Capital Downgrades Electronic Arts to Market Perform, Lowers Price Target to $145

JP Morgan analyst Matthew Boss downgrades Acushnet Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLF#NYSE">GOLF</a>) from Neutral to Underweight and announces $64 price target.

Comments

Industry Source

Industry Source (INSO) Forecast

Industry Source (OTC:INSO) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga